Document Detail

Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.
MedLine Citation:
PMID:  18808529     Owner:  NLM     Status:  MEDLINE    
The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed. Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol. Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins. We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration. Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix. The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin. Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process. In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte. These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.
Erica C Campos; Minna M D Romano; Cibele M Prado; Marcos A Rossi
Related Documents :
17890289 - Comparative effects of acute vs. chronic oral amiodarone treatment during acute myocard...
8897839 - Endotoxin induces cardiac hsp70 and resistance to endotoxemic myocardial depression in ...
2968479 - Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compl...
22975439 - Clinical endpoint adjudication in a contemporary all-comers coronary stent investigatio...
17394569 - Enhanced beta-adrenergic response in rat papillary muscle by inhibition of inducible ni...
1506079 - Failure to reduce experimental myocardial infarct size with ibuprofen pre-treatment in ...
21831889 - Multi-scale computational models of familial hypertrophic cardiomyopathy: genotype to p...
11225939 - Does the mechanism of action of biatrial pacing for atrial fibrillation involve changes...
17255819 - Pediatric arrhythmias: which are the news?
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of experimental pathology     Volume:  89     ISSN:  1365-2613     ISO Abbreviation:  Int J Exp Pathol     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-09-23     Completed Date:  2008-12-04     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  9014042     Medline TA:  Int J Exp Pathol     Country:  England    
Other Details:
Languages:  eng     Pagination:  367-81     Citation Subset:  IM    
Department of Pathology (Cellular and Molecular Cardiology), Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Actins / analysis,  metabolism
Adrenergic beta-Agonists / adverse effects*
Antigens, CD29 / analysis
Cardiomyopathies / chemically induced*,  immunology,  metabolism
Dystrophin / analysis*,  metabolism
Fluorescent Antibody Technique
Isoproterenol / adverse effects*
Laminin / analysis,  metabolism
Macrophages / immunology
Myocardium / immunology,  metabolism*,  pathology
Nitric Oxide Synthase Type III / analysis
Sarcoglycans / analysis,  metabolism
Sarcolemma / chemistry,  metabolism
Reg. No./Substance:
0/Actins; 0/Adrenergic beta-Agonists; 0/Antigens, CD29; 0/Dystrophin; 0/Laminin; 0/Sarcoglycans; 0/laminin alpha 2; 146888-27-9/Dystroglycans; 7683-59-2/Isoproterenol; EC Oxide Synthase Type III

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adverse effect of the anabolic-androgenic steroid mesterolone on cardiac remodelling and lipoprotein...
Next Document:  L-arginine ameliorates experimental autoimmune myocarditis by maintaining extracellular matrix and r...